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ABSTRACT
Biomedical advances are transforming the diagnosis and treatment of disease.
Patienthood is also transforming, as patients actively participate in research,
innovation and regulation of novel technologies and therapies. In this paper we
explore the new kinds of practices that patients are performing in their roles as
research subject, co-researchers, donors, campaigners, representatives and
consumers of novel stratified therapies. We outline their embodied contributions
to clinical trials, biobanks and stratified therapies prior to, during and after
having cancer. Exploring how patienthood involves donating more than tissue
or data to these developments, we consider their emotional and identity work
which informs and shapes the novel diagnostics and therapies being developed.
We also consider how this kind of work is stratified according to the social and
biological location of participants, and end by reflecting on the implications of
our analysis for the organisation and regulation of biomedicine.
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1. Introduction
Across the twentieth century and into the current century we have seen wide-
spread advances in our abilities to prevent, detect and treat a range of diseases.
Rapid developments in the so-called ‘post-genomic’ research and medicine
also offer the possibility of much more targeted interventions to prevent
and tackle diseases, turning conditions like cancers into chronic rather than
terminal conditions. These developments in medical science and technologies
are celebrated in popular and policy narratives because of their potential to
improve our lives and ensuring an effective and efficient health care system.
Yet this agenda comes with risks and questions attached. Most notably, exten-
sive research, monitoring and interventions in the interests of conquering
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disease has the potential to make patients of us all as we attend to the possi-
bility of developing or lapsing into disease through the lifecourse.1
Being a patient in the contemporary post-genomic era is freighted with
moral and political decisions, social practices and new organisational forms.
This raises questions about the ways in which biomedical research, diagnosing,
monitoring and treatment of disease or its possibilities are changing patient-
hood, bringing new demands for particular kinds of emotional and embodied
practices on the part of patients or patients-in-waiting.2 As sociologists of bio-
medicine have argued, we need to think carefully about how these practices are
distributed, experienced and valued, and theways inwhich this is reconfiguring
the implicit contract between the individual and the healthcare system.3
This means engaging with the interactions which make up the experiences
and notions of contemporary patients, not just amongst and between patients
and doctors, but across the innovation spectrum, including more hidden pro-
cesses of patient involvement and representation in biobanking, trials and
data analytics and cultural industries of social media and patient advocacy.4
To explore this we need to approach patienthood as dynamic, multi-faceted
and performative – as woven from a web of socio-technical processes
rather than fixed in individual experiences or attributes.5 We need to under-
stand these processes, not by normative argument about whether one would
or should uptake new technology, but by considering how bodies, emotions
and subjectivity feature in a wider set of decisions and discussions about effi-
cacy, use and entitlements to biomedical technoscience.6
1Carlos Novas and Nikolas Rose, ‘Genetic Risk and the Birth of the Somatic Individual’ (2000) 29 Economy
and Society 485; Adele E Clarke, ‘Biomedicalization’ in William Cockerham, Robert Dingwall and Stella
R. Quah (eds), The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society (Wiley-Blackwell,
2014); S Scott, L Prior, F Wood and J Gray, ‘Repositioning the Patient: The Implications of Being “At Risk”’
(2005) 60 Social Science & Medicine 1869.
2Kirsten Bell, ‘Biomarkers, the Molecular Gaze and the Transformation of Cancer Survivorship’ (2013) 8 Bio-
societies 124; Eric J Cassell, The Nature of Suffering and the Goals of Medicine (Oxford University Press, 2nd
edn 2004); Kyra Landzelius, ‘Introduction: Patient Organization Movements and New Metamorphoses in
Patienthood’ (2006) 62 Social Science & Medicine 529; Nicky James, ‘Emotional Labor: Skill and Work in
the Social Regulation of Feelings’ (1989) 37 Sociological Review 15.
3Catherine Waldby, ‘Stem Cells, Tissue Cultures and the Production of Biovalue’ (2002) 6 Health 305; Carlos
Novas, ‘The Political Economy of Hope: Patients’ Organizations, Science and Biovalue’ (2006) 1 Biosoci-
eties 289; Nikolas Rose and Carlos Novas, ‘Biological Citizenship’ in Aihwa Ong and Stephen J Collier
(eds), Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems (Blackwell,
2005); Catherine M Will, ‘Mutual Benefit, Added Value? Doing Research in the National Health
Service’ (2011) 4 Journal of Cultural Economy 11.
4Aline Sarradon-Eck, Juliette Sakoyan, Alice Desclaux et al, ‘“They Should Take Time”: Disclosure of Clinical
Trial Results as Part of a Social Relationship’ (2012) 75 Social Science & Medicine 873; Richard Tutton and
Barbara Prainsack, ‘Enterprising or Altruistic Selves? Making up Research Subjects in Genetics Research’
(2011) 33 Sociology of Health & Illness 1081; Richard Tutton, ‘Personalizing Medicine: Futures Present and
Past’ (2012) 75 Social Science & Medicine 1721; Effy Vayena and Barbara Prainsack, ‘Regulating Genomics:
Time for a Broader Vision’ (2013) 5 Science Translational Medicine 1.
5Adele E Clarke, Janet K Shim, Laura Mamo et al, ‘Biomedicalization: Technoscientific Transformations of
Health, Illness, and US Biomedicine’ (2003) 68 American Sociological Review 161.
6Gayle A Sulik, ‘Managing Biomedical Uncertainty: The Technoscientific Illness Identity’ (2009) 31 Sociology
of Health & Illness 1059.
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Although there is clearly a need to consider the embodied subjectivities of
all of the different actors who encounter biomedicine – scientists, healthcare
practitioners, policymakers – here we turn our attention to patients’ bodies,
given that these are principal bodies on which technoscience impinges and
indeed develops. We focus on how their bodies and emotions co-produce
the innovation and regulation of biomedical technoscience.7 If patients are,
like philosophers, seeking particular answers to their condition, and the
human condition besides, how is this achieved via their bodies and technol-
ogies combined? And what of the patients who do not participate or are
not acknowledged in these processes? What is their embodied experience
and relationship to biomedical innovation and regulation; where does the
resource offered by their body generate value; and who benefits? As this
mention of value reminds us, patients are increasingly asked to participate
in biomedical innovation as research subjects, evaluators, monitors, cam-
paigners, commentators, donors and fund-raisers. Despite the fact that
these practices generate value, they are not often considered or remunerated
as ‘work’. There is also little reflection on what kinds of patients are able and
willing to contribute in these ways.8
To explore these questions we focus our attention on cancer in the post-
genomics era. We have chosen cancer because it is both ubiquitous and the
site of rapid biomedical advancement. It is estimated that more than one in
three people will be diagnosed with cancer over the course of their lives,9
and so almost everyone is touched by cancer as family members, friends,
charitable donors and citizens. Nevertheless, these experiences vary dramati-
cally as the stubborn deprivation gap in the incidence and prognosis of cancer
attests.10 Inflected through the politics of gender, class, age and ethnicity,
experiences of cancers vary dramatically. At the same time rapid develop-
ments in cancer genomics have introduced new clinical trials, treatment
regimes and monitoring practices.11
7Steven Epstein, Impure Science: AIDS, Activism, and the Politics of Knowledge (University of California Press,
1996); J Francisca Caron-Flinterman, Jacqueline EW Broerse and Joske FG Bunders, ‘Patient Partnership in
Decision-Making on Biomedical Research: Changing the Network’ (2007) 32 Science Technology & Human
Values 339; Michel Callon and Vololona Rabeharisoa, ‘The Growing Engagement of Emergent Concerned
Groups in Political and Economic Life: Lessons from the French Association of Neuromuscular Disease
Patients’ (2008) 33 Science Technology & Human Values 230.
8For an important recent contribution on the work of donation and research subjects by non-patients, see
Melinda Cooper and Catherine Waldby, Clinical Labor: Tissue Donors and Research Subjects in the Global
Bioeconomy (Duke University Press, 2014).
9PD Sasieni, J Shelton, N Ormiston-Smith et al, ‘What is the Lifetime Risk of Developing Cancer?: The Effect
of Adjusting for Multiple Primaries’ (2011) 105 British Journal of Cancer 460.
10B Rachet, LM Woods, E Mitry et al, ‘Cancer Survival in England and Wales at the End of the 20th Century’
(2008) 99 British Journal of Cancer S2; J Ferlay, I Soerjomataram, M Ervik et al, ‘GLOBOCAN 2012 v1.0,
Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11’ (International Agency for Research
on Cancer, 2013) http://globocan.iarc.fr (accessed 26 March 2015).
11Eric T Juengst, Michael A Flatt and Richard A Settersten Jr, ‘Personalized Genomic Medicine and the
Rhetoric of Empowerment’ (2012) 42 Hastings Center Report 42 (5): 34–40; Alberto Ocana and Atanasio
Pandiella, ‘Personalized Therapies in the Cancer “Omics” Era’ (2010) 9 Molecular Cancer.
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There is also a veritable industry of charitable donations, research initiat-
ives, treatment centres and cultural products associated with cancer where
patients are consumers and producers of the disease, diagnosis and therapy.
Cancer is at the frontier of novel ways of ‘doing medicine and health care’,
embracing Prediction, Prevention, Personalisation and Participation, or the
‘P4 paradigm’ as it is known in biomedicine.12 Patients’ bodies are involved
in myriad ways with contemporary cancer research, innovation, care and
regulation. In what follows we explore three key sites of embodied biomedical
innovation and regulation: (i) cancer drugs trials (ii) national genomics data
initiatives and (iii) public funding for targeted treatments, in order to think
more broadly about the ways (particular kinds of) patients bodies are impli-
cated in innovation and regulation in the post-genomics era.
2. Being on trial
Participation in clinical trials is now an established part of cancer therapy for
growing numbers of patients, not just those at an advanced stage of the
disease.13 This is reflected in the practices of large national organisations
like Cancer Research UK, who provide ‘Find a Trial’ services online to give
patients the chance to access new therapies. As drugs have developed to
target particular configurations of cancer genomics, patients can search
according to their cancer subtype, as well as the drug the trial involves.
Patients groups are also actively involved in campaigning to increase access
to trials amongst their constituencies, working in partnership with trial pro-
viders across the private and public sectors.14 As Moreira and Wills have
argued, debates about design, organisation, and evaluation extend beyond
the clinical community involving patients in new ways, as consumers and pro-
ducers of trials and their results.15
However, this proliferation of trials rests on an uneasy tension around the
public and personal benefits of trial participation.16 The scientific logic of later
phase trials is that participants are assigned randomly to the new experimental
12Leroy Hood and Mauricio Flores, ‘A Personal View on Systems Medicine and the Emergence of Proactive
P4 Medicine: Predictive, Preventive, Personalized and Participatory’ (2012) 29 New Biotechnology 613.
13Peter Keating and Alberto Cambrosio, Cancer on Trial: Oncology as a New Style of Practice (University of
Chicago Press, 2012); Sarradon-Eck et al (n 4); Vinh-Kim Nguyen, ‘Antiretroviral Globalism, Biopolitics,
and Therapeutic Citizenship’ in Aihwa Ong and Stephen J Collier (eds), Global Assemblages: Technology,
Politics, and Ethics as Anthropological Problems (Blackwell, 2008); Tiago Moreira and Paolo Palladino,
‘“Population Laboratories” or “Laboratory Populations”? Making Sense of the Baltimore Longitudinal
Study of Aging, 1965–1987’ (2011) 42 Studies in History and Philosophy of Biological and Biomedical
Sciences 317.
14Aaron Panofsky, ‘Generating Sociability to Drive Science: Patient Advocacy Organizations and Genetics
Research’ (2011) 41 Social Studies of Science 31.
15Catherine Will and Tiago Moreira (eds), Medical Proofs, Social Experiments: Clinical Trials in Shifting Con-
texts (Ashgate, 2010).
16Oonagh Corrigan, ‘Empty Ethics: The Problem with Informed Consent’ (2003) 25 Sociology of Health &
Illness 768.
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treatment or the ‘control’ arm of the trial which uses conventional treatment,
in order that the safety and efficacy of the new drug can be established; as a
result new trial designs have to embrace molecular stratification through
ever more complex protocols. But it is widely recognised that patients often
join these trials because they want to access the experimental treatment, in
the hope that it will prove to be more effective than conventional treatment.17
Participation in trials has, for many professionals and patients, become an
established part of contemporary cancer care. Their proliferation means
that cancer professionals, whether in developed or developing countries,
work across research and clinical practice, negotiating and reproducing ten-
sions around altruistic and personal benefits when engaging with patients
taking part in trials. As Catherine Will has found in ethnographic research,
professionals’ ‘formal and informal strategies for living with this distinction
may have the unintended consequence of making research appear sup-
plementary to rather than simply different from clinical care’.18
This involves patients in devoting time and energy to involving themselves
as trial participants – providing information and updates, travelling to trial
sites and interviews and keeping a close eye on their health and any side-
effects from treatment. This situation is further complicated by the targeting
of trials and treatment; in order to achieve the required number of partici-
pants, trials may increasingly require patients to travel. Patients make this
kind of investment in travel and experimental treatment not simply because
of a sense of altruism but because of a desire to access treatments not available
locally. In countries where publically funded healthcare is not widely avail-
able, participating in commercially organised trials can also be a route to con-
ventional treatments and better basic healthcare. As Petryna notes, there is a
wide diversity of investments and experiences of trials amongst patients,
depending on their social location and the progression of their illness. For
those who are very ill or impoverished, clinical trials might present ‘their
best medical option rather than…“mere” experimentation’, and for others
trials might also be a source of income.19 However, there have been ethical
dilemmas regarding participation in cancer screening trials, the control
arms of which do not necessarily give access to standard treatments available
in other countries but not typically in the location of the trial.20
17Christopher Daugherty, Mark J Ratain, Eugene Grochowski et al, ‘Perceptions of Cancer Patients and their
Physicians Involved in Phase I Trials’ (1995) 13 Journal of Clinical Oncology 1062; Katie Featherstone and
Jenny L Donovan, ‘“Why Don’t They Just Tell Me Straight, Why Allocate It?”: The Struggle to Make Sense
of Participating in a Randomised Controlled Trial’ (2002) 55 Social Science & Medicine 709; Mary Dixon-
Woods and Carolyn Tarrant, ‘Why Do People Cooperate with Medical Research? Findings from Three
Studies’ (2009) 68 Social Science & Medicine 2215.
18See Will (n 3) 11.
19Adriana Petryna, When Experiments Travel: Clinical Trials and the Global Search for Human Subjects (Prin-
ceton University Press, 2009) 2–3.
20Eric J Suba, ‘US-funded Measurements of Cervical Cancer Death Rates in India: Scientific and Ethical Con-
cerns’ (2014) 11 Indian Journal of Medical Ethics 167.
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Despite this proliferation of trials, there is little qualitative information on
patients’ experiences of participation or non-participation in novel cancer
trials, particularly the kinds of embodied, emotional practices this involves
for some (but not all) patients. Most of the data available are based on quan-
titative measures of quality of life conducted or participant experiences as part
of the trial evaluations and piloting to improve trial design and operating pro-
cedures.21 There are, however, a number of patient testimonies online that
give some insights into what it is like to be ‘on trial’, albeit typically from a
privileged, largely middle-class, perspective. These narratives are performa-
tive,22 in that they constitute part of the work patients do in participating
in trials. Such stories about trial participation typically form part of a clinical
trial organisation’s website and comprise one way in which people can be
encouraged to join clinical trials; they also create the hybrid identity of
patient/research subject. For example, in the Stanford Cancer Institute
blog,23 patients give testimony about the value and benefits of being in a
trial, describing their emotional journey from diagnosis through treatment
to survivorship. Trials here are presented as their ‘best option’ and doctors
as ‘healers’ who are offering patients the chance of the most advanced
treatments.
In these accounts, survivors emphasise the need to be hopeful and pro-
active rather than fearful or passive in the face of cancer. In accounting for
the sacrifice of travelling long distances to take part in trials because of the
benefits this could bring to their own health and the future of a cure for
others, and telling stories of hope, sacrifice and participation, participants
are doing emotional work24 as well as embodied physical work as part of
being on trial and producing value in the bioeconomy. Discourses of hope
are produced and reproduced through the clinical trials industry and
patient narratives about their involvement in novel trials. Research suggests
that, in relation to trials generally, patients hope that they are in the treatment
arm,25 and that consent to randomisation is not fully informed, raising
21Nicola Mills, Jane M Blazeby, Freddie C Hamdy et al, ‘Training Recruiters to Randomized Trials to Facili-
tate Recruitment and Informed Consent by Exploring Patients’ Treatment Preferences’ (2014) 15 Trials
323.
22Judith Butler, ‘Performative Acts and Gender Constitution: An Essay in Phenomenology and Feminist
Theory’ (1988) 40 Theatre Journal 519; Judith Butler, Undoing Gender (Routledge, 2004).
23Patient Stories Patients share their experiences with participating in clinical trials. Stanford Medicine
Cancer Institute Stanford CA, http://med.stanford.edu/cancer/trials/patient-stories.html (accessed 5
November 2015).
24See James (n 2); Arlie Hochschild, The Managed Heart: Commercialization of Human Feeling (University of
California Press, 3rd edn 2012).
25Chiara Catania, Tommaso De Pas, Aron Goldhirsch et al, ‘Participation in Clinical Trials as Viewed by the
Patient: Understanding Cultural and Emotional Aspects which Influence Choice’ (2008) 74 Oncology 177;
D Lindström, I Sundberg-Petersson et al, ‘Disappointment and Drop-Out Rate after Being Allocated to
Control Group in a Smoking Cessation Trial’ (2010) 31 Contemporary Clinical Trials 22; Sandra Meinich
Petersen, Vibeke Zoffmann, Jesper Kjaergaard et al, ‘Disappointment and Adherence Among Parents
of Newborns Allocated to the Control Group: A Qualitative Study of a Randomized Clinical Trial’
(2014) 15 Trials 126.
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challenges for patients and clinicians and others engaged in clinical trial
recruitment.26 New cancer trials in the era of stratified medicine may
reshape discourses of hope embedded in the relationship between patient,
trial recruiter and trial organisation and the role of drug treatment.
There are, however, less welcome emotions and bad feelings to be nego-
tiated as part of trial participation too, although these kinds of practices are
not well documented. One report by Eli Lilly,27 a large trial provider, never-
theless gives some glimpses into this, noting patients’ disappointments and
poor experiences with exclusion, information, consent forms, recruitment
and the ending of trials. This can include not being able to access the trial
at all, the level of medical support they would like during or after the trial,
or finding out that they have been on the ‘control’ arm of the trial as
opposed to the new treatment, and so have not had any potential advantage
from their participation. These experiences highlight the uneasy tensions
around patients’ sense of entitlements to participate and benefit from trials,
profit and the provision of public benefit by virtue of their participation.
This suggests a reconfiguring of relationships between clinical care and
research: being a patient, a research participant and a good biological
citizen involves emotional work to handle the conflicting sense of responsibil-
ities and rights involved.28
Attention has also recently turned to the fact that patients’ experience of
side effects during their participation in trials are not always taken into
account in the reporting and analysis of the trial results, because they can
be ‘filtered’ by clinicians in such a way as to downgrade the severity of
certain symptoms or even miss them entirely. Initiatives are now underway
to address these deficiencies, through patients reporting directly on symptoms
as part of the trial design,29 for example via digital technologies to enable ‘real-
time’ reporting of their symptoms and side-effects: a form of ‘participatory
ethnography’ using mobile phones.30 As some respondents in the Lilly
report noted, however, this brings additional responsibilities to patients to
act as data-recorders, which can be demanding, especially if the recording
template is not easy to complete.
26See Featherstone and Donovan (n 17); C Behrendt, T Goelz, C Roesler et al, ‘What Do Our Patients Under-
stand About Their Trial Participation? Assessing Patients’ Understanding of Their Informed Consent Con-
sultation About Randomised Clinical Trials’ (2011) 37 Journal of Medical Ethics 74.
27Eli Lilly & Company, ‘Improving the Patient Experience of Clinical Trials’ London, 17 April 2014 www.lilly.
co.uk/global/img/UK/Patient/Lilly-PAG-Report-FINAL-WEB-COPY.pdf accessed 6 October 2014.
28See Rose and Novas (n 3).
29Ethan Basch, ‘The Missing Voice of Patients in Drug-Safety Reporting’ (2010) 362 New England Journal of
Medicine 865.
30Ethan Basch and Amy P Abernethy, ‘Supporting Clinical Practice Decisions With Real-Time Patient-
Reported Outcomes’ (2011) 29 Journal of Clinical Oncology 954; Clark C Freifeld, Rumi Chunara,
Sumiko R Mekaru et al, ‘Participatory Epidemiology: Use of Mobile Phones for Community-Based
Health Reporting’ (2010) 7(12) PloS Med e1000376.
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Patients’ participation in trials is also extending as some of them become
more involved in evaluation of trials and efforts to redesign them to
improve participation and experiences, with much of this work focusing on
how to improve patient understanding of the randomisation process in
order to manage expectations of the trial.31 The Lilly report also points to
patients’ interests in giving more information to staff about how their lives
were affected by being on the trial and in exchanging emotional support
with other patients and families, perhaps in the form of a support group.
These developments put patients’ emotions to work in new ways, to
support themselves and each other via exchange of information.
The expansion of clinical trials beyond the affluent West, particularly for
vaccines for cancers such as cervical cancer (the biggest killer of women in
the developing world), also brings new but different kinds of participatory
practices. These trials give more women access to screening and treatments
that are not otherwise available; but, there are many ethical and legal tensions
around their funding, design and the processes of obtaining informed
consent. There is an industry of commercial organisations involved in a
global search for participants in trials.32 The low costs of running trials in
developing countries and history of limited access to treatments amongst
potential participants makes them attractive to pharmaceutical companies,
but there have been controversies and allegations of under-reporting side-
effects, and implicit coercion of participants in these trials because of their
fears that their access to healthcare for their family would be compromised
should they decline to take part. Participating in trials in these contexts trans-
forms patients’ bodies into a resource for the family, and involves the
emotional work of managing responsibilities and obligations to kin.33
Taken together these developments suggest a broadening and deepening of
patients’ involvement in designing, considering, participating in, evaluating
and recruiting others to clinical trials, drawing on their embodied experiences
and emotions when having treatment and managing and recording its effects.
As Jespersen and colleagues have noted, clinical trials involve participants in
‘entangled processes of bodywork, where data are extracted, objectified bodies
are manipulated and care practices address the emotional, social and
mundane aspects of the participants’ everyday lives’.34 There has also been
a growth in the numbers of patients who are involved in trials as a routine
part of their treatment and pressures to include more diverse populations
31JL Donovan, L Brindle and N Mills, ‘Capturing Users’ Experiences of Participating in Cancer Trials’ (2002)
11 European Journal of Cancer Care 210.
32See Petryna (n 19).
33SciDev Net, ‘Ethics left behind as drug trials soar in developing countries’ The Guardian (London, 4 July
2011) www.theguardian.com/global-development/2011/jul/04/ethics-left-behind-drug-trials-developing
(accessed 6 October 2014).
34Astrid P Jespersen, Julie Bonnelycke and Hanne H Eriksen, ‘Careful Science? Bodywork and Care Practices
in Randomised Clinical Trials’ (2014) 36 Sociology of Health & Illness 655.
194 A. KERR AND S. CUNNINGHAM-BURLEY
in trials to improve applicability of results, which means that these practices
are now being performed by more diverse kinds of bodies. However, there are
clearly very different kinds of practices by participants depending on their
position on the spectrum of affluent, active and articulate patients at once
involved in challenging and co-producing trials and their results to deprived,
vulnerable and dependent patients who are more likely to be providing their
bodies as resources for the trial in exchange for more basic kinds of care for
themselves and their families which affluent patients might take for granted.
But, taken together, these practices make trials work, enabling corporations
and healthcare bodies to develop and market treatments that generate both
private and public benefit. Participants in trials leave their biological, social
and emotional traces in the data, technologies and discourses they produce,
but the work involved in their generation is largely invisible.
3. Genomes ‘r’ us
In addition to their participation in clinical trials, patients and populations
are increasingly involved in a range of large-scale biobanking initiatives. As
a global example of neoliberalist tendencies in health and medical science,
such initiatives enjoin novel ‘technologies of the self’, where individuals
donate tissue, health and social information to research institutions which
then mine the vast corpus of data this generates for associations between
particular kinds of diseases and biological/social characteristics.35 In the
era of high throughput sequencing and multi-national, globalised partner-
ships across the scientific community and biomedical industries, these
initiatives are becoming an important part of national health research infra-
structure, as the recent development of the 100,000 Genome Project in the
UK demonstrates. This project aims to sequence 100,000 whole genomes
from National Health Service (NHS) patients and their families affected
by a range of diseases, currently focusing on rare disease, cancer and infec-
tious disease. It was established by the Department of Health, with a remit
to bring genomic medicine to the NHS and ‘kick start the development of a
UK genomics industry’.36 Like other post-genomic initiatives, the 100,000
Genome Project brings together national healthcare systems, publically
funded laboratories, patients’ organisations and patients’ bodies in order
to generate a vast array of biological data, including whole-genome, and
social information as a platform for innovation, including by the global
pharmaceutical industry. Here too, as with trials, we find a melding of
35Oonagh Corrigan and Richard Tutton, Genetic Databases: Socio-Ethical Issues in the Collection and Use of
DNA (Psychology Press, 2004); Klaus Hoeyer, ‘The Ethics of Research Biobanking: A Critical Review of the
Literature’ (2008) 25 Biotechnology and Genetic Engineering Reviews 429; Herbert Gottweis and Alan
Petersen (eds), Biobanks: Governance in Comparative Perspective (Routledge, 2008).
36Genomics England, Department of Health www.genomicsengland.co.uk/about-genomics-england/how-
we-work (accessed 26 January 2015).
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care and research, as participants at once provide samples, data and support
for repositories and further commercial developments, and receive more
regular contact with health practitioner, health monitoring and feedback
as a consequence of their participation.
To understand how participating in these initiatives extends the practices
of patients and their families we can turn to explore the processes through
which they give their consent, and some of the challenges to existing
systems of informed consent that this brings. The complex networks
through which these platforms are developed and utilised, particularly the
dynamic research agenda and multiplicity of potential users of stored
tissues and data over time, has challenged traditional processes of informed
consent and led to a range of models which also demand other kinds of embo-
died work from donors and participants.37 One such model, for example, is
that of ‘dynamic consent’, whereby participants maintain a connection to
the repository and give consent to particular uses of their data over the
course of their lives.38 However, the complexities and challenges of this
model have led some to call for a different more collective model of
consent where members of the public act, on behalf of donors, as custodians
of their data.39 Custodial responsibilities include the need to be educated and
informed about the kinds of data and science being performed and to be able
to imagine how others might feel about their data being used in particular
ways. As with patients involved in clinical trials, we find a proliferation of
patients donating to or overseeing biobanks on behalf of other donors.
These patients are being asked to donate time, intellectual and emotional
work as well as data and tissues that they have produced through their embo-
died, social agency. This ‘responsibilisation’40 of patienthood brings their
labour directly into the production of scientific knowledge and novel health-
care interventions.
These new responsibilities for patients involved in biobanking sit alongside
an intensification of what Hoeyer calls ‘ethics work’ that has grown as part of
their infrastructures, which includes obligations for donors as well as custo-
dians to reflect on their relationship to their donated materials in new
ways.41 As Knoppers et al have also argued, ‘the data deluge that is already
engulfing biostatisticians may soon be repeated for citizens’ as they have to
work out what they do and do not want to know as findings from biobanks
37Keating and Cambrosio (n 13).
38Jane Kaye, Edgar A Whitley, David Lund et al, ‘Dynamic Consent: A Patient Interface for Twenty-First
Century Research Networks’ (2015) 23 European Journal of Human Genetics 141.
39Kostas Kampourakis, Effy Vayena, Christina Mitropoulou et al, ‘Key Challenges for Next-Generation Phar-
macogenomics’ (2014) 15 Embo Reports 472.
40G Burchell, ‘Liberal Government and Techniques of the Self’ (1993) 22 Economy and Society 267.
41Klaus Hoeyer, ‘Size Matters: The Ethical, Legal, and Social Issues Surrounding Large-Scale Genetic
Biobank Initiatives’ (2012) 21 Norsk Epidemiologi 211.
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emerge.42 This requires particular kinds of embodied reflection and decision-
making on the part of participants who might be asked whether or not they
would like to know or they think others would want to know about how
their bodies respond to particular drugs, their propensity to develop certain dis-
eases in the future for which there are not necessarily preventative measures to
be taken, and their capacity to live with the uncertainties this information might
generate, should they opt to receive it. To be in a position to form a view or
respond to these types of questions participants must draw on their embodied
‘stock of knowledge’43 about other healthcare experiences and project their
selves into the future to imagine how they might feel about other kinds of
uncertainties and risks in their lives. These practices are forms of work on
one’s self and one’s futures, involving emotional and ethical management of
identity and belonging for individuals, families and patient communities.
The extent to which donors might take on this kind of work, of course,
varies according to the location, size and longevity of the projects and initiat-
ives with which they are associated but there is evidence to suggest these
initiatives are becoming longer and larger over time, changing the nature of
participants’ involvement. For example, increasing recognition of the com-
plexity and heterogeneity of cancer has prompted the integration of insti-
tutional biobanks with a view to providing more comprehensive resources
of biological and lifestyle information for translational medicine and targeted
therapies and interventions.44 This agglomeration has produced large-scale
biobanks where donated tissues and data are shared internationally. This
raises questions about what kinds of practices are required to transform
and steward patients’ data in these complex initiatives, including how
patients’ views are represented in this process, for example via global proto-
cols and procedures required to align these banks for research. Here custo-
dians of biobanks, including some patients or former patients, must grapple
with how patients’ and donors’ emotions and values are to be traced and
worked upon in these extended research processes.
These questions are particularly important in the context of the obligations
and entitlements of national or global citizenship within which biobanks
operate. When biobanks are positioned as national assets, donation is associ-
ated with the duties of national citizenship. For example, countries like the UK
have sought to position their comprehensive NHS as an invaluable network of
resource generation, recruiting patients as donors and building up a database
which will form part of the growing biomedical sector in the UK and attract
investment from pharmaceutical companies who will pay to access the
42Bartha Maria Knoppers, Ma’n H Zawati and Emily S Kirby, ‘Sampling Populations of Humans Across the
World: ELSI Issues’ (2012) 13 Annual Review of Genomics and Human Genetics 395.
43Alfred Schutz, A Phenomenology of the Social World (Heinemann Educational Books 1972).
44R William G Watson, Elaine W Kay and David Smith, ‘Integrating Biobanks: Addressing the Practical and
Ethical Issues to Deliver a Valuable Tool for Cancer Research’ (2010) 10 Nature Reviews Cancer 646.
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information. Here becoming a donor or a ‘lay representative’ is presented as
an extension of the obligations of patienthood – a way for patients to ‘give
back’ to the nation and grow the bioeconomy for the benefit of future gener-
ations. To donate is to make an emotional and material connection with the
NHS, the nation and its future citizens.
Biobanks are also configuring patient advocacy in new ways, forming an
important dimension of their efforts to support and progress research into
their condition. Many disease-specific biobanks have strong relationships
with patient advocates, which are vital in the recruitment of donors, particu-
larly for rare diseases.45 Knoppers and colleagues give the example of the
Genetic Alliance BioBank,46 a network of genetic advocacy groups, which
has provided 10,000 samples/records to this biobank. Being this kind of
active patient involves work to constitute the biobank initiative and generate
benefit from its results – patients are also involved in lobbying large national
and international banking initiatives to focus attention on the particular type
or subtype of disease the group represents, potentially competing with other
kinds of rare or common cancers, and implicitly different social groups
according to class, race, gender and age (given that cancer is stratified accord-
ing to social location as well as genetics). For many advocates these banks are
not likely to generate direct, personal health improvements, so their invest-
ment is in future health benefits for their fellow sufferers or families in the
case of hereditary diseases. Patients involved in these kinds of advocacy
organisations are however central to the ethical apparatus of these biobanks,
forming a resource not just for samples and data but ethical reflection and
perspectives which is now routinely gathered as the banks set up their oper-
ational and governance procedures. Patient representatives like these are
active parties in the production of consent forms and data confidentiality pro-
cedures, especially where there are concerns about information becoming
accessible to third parties, like insurance companies, and there is a perceived
need to protect donors from potential discrimination.
It is also important to note that patient involvement in establishing,
resourcing and overseeing biobanks is patterned according to class and
social location, with particularly stark contrasts to be found between the
work expected of ‘donors’ in affluent and developing countries.47 The
history of biobanking in developing countries is marked by colonial
relations, and there continue to be concerns over the exploitation of
donors as research ‘objects’ rather than active subjects. This has prompted
a range of activist organisations to campaign for consultation with
45See Knoppers et al (n 42).
46www.biobank.org (accessed 27 March 2015).
47Margaret Sleeboom-Faulkner (ed), Human Genetic Biobanks in Asia: Politics of Trust and Scientific
Advancement (Routledge, 2009).
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prospective participants about the design of the biobank48 and brought
issues of benefit sharing, with donors and communities, into sharp relief.
There have also been disputes over the generation of intellectual property
from these banks, particularly for global multinationals who are able to
access results and generate treatments whilst the donors remain in countries
with poor healthcare provision.
Patient participation in cancer biobanks, then, is not a straightforward
matter of donating tissues and data, but of actively negotiating a much wider
terrain of embodied participation that articulates a range of entitlements and
obligations around citizenship, family and disease-group. This includes
patients who are directly involved as donors as well as those recruited to the
business of ‘ethics work’ or politics around privacy, ownership, resources
and recruitment to the databases. Donation or oversight requires that patients
draw from and reflect on their own and their fellow patients’ experiences, per-
spectives and emotional responses to particular developments and opportu-
nities as they evolve, rather than a simple ‘giving over’ of their bodily tissue
or personal information. However, not all patients are in the same position
to participate in the constitution or oversight of biobanks, or to experience
the rewards that this kind of activitymight generate, for their identity, personal
health or financial security or that of their family/fellow patients in the future.
While recognising that the agency of individual patients and their collectives
actively shapes their involvement in neoliberal scientific enterprises, such as
biobanks, including not to become involved, othersmay feel or be activelymar-
ginalised through these processes. Biobanks rely on patients’ emotional
donations and reflections beyond the period of their active donation, utilising
the affective investments of individuals for the benefits of the nation and the
various corporate bodies through which this is to be realised.
4. Public funding for targeted treatments
So far we have considered a range of practices associated with being a
patient-participant in biomedical research in the post-genomics era,
especially the emotional and ethical work associated with managing the
hopes, challenges and obligations of involvement during and beyond the
period of active donation or participation in trials and what patient repre-
sentatives do when they negotiate the governance, stewardship, benefit
sharing and future possibilities of these kinds of initiatives.49 We now
turn to consider the demands and emotions associated with accessing
48Margaret Lock, ‘Interrogating the Human Diversity Genome Project’ (1994) 39 Social Science & Medicine
603.
49Callon and Rabeharisoa (n 7); Tutton and Prainsack (n 4); Courtney Davis and John Abraham, ‘Desperately
Seeking Cancer Drugs: Explaining the Emergence and Outcomes of Accelerated Pharmaceutical Regu-
lation’ (2011) 33 Sociology of Health & Illness 731.
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novel treatments and therapies in the post-genomic era, and the kinds of
practices involved in managing the different kinds of clinical, institutional
and policy challenges these can bring.
The post-genomic era has brought with it a panoply of expensive cancer
drugs for particular sub-types of common cancers like breast or prostate
cancer. These drugs are not universally available because of their high costs
and the mixed economy of provision across different jurisdictions. In some
countries with healthcare systems based on personal insurance cover, the
drugs are available to those on the most comprehensive schemes whilst others
with no or only basic insurance will not be covered and are unlikely to be able
to fund the treatment themselves. In countries with national health services,
such as the NHS in the UK, regulation of access to the drugs is complex.
Decision-making about drug funding is subject to intense government scrutiny
and comment by a range of organisations and companies, including the drug
companies involved in manufacturing and setting the price for these drugs
and patient and charitable organisations as well as patient and public commen-
tators across social media. In England until recently, this involved two bodies
with different remits – the Cancer Drug Fund and the National Institute for
Care and Excellence (NICE). The methodologies used by organisations like
NICE to assess whether or not to fund expensive drugs rely onHealth Technol-
ogyAssessment algorithmswhich attempt toquantify quality of life, for example
the Quality Adjusted Life Year (QALY). These processes of assessment often
mean that cancer drugs are deemed too expensive.
Organisations like NICE also function on the public stage, with its leading
members actively involving themselves in debates about the need for drug
companies to price responsibly and for the nation state to make difficult
decisions which balance individual patients’ interests with that of the public
more generally, given the finite budgets available for healthcare. The
Cancer Drug Fund is also a highly political body. Set up in 2010 because
cancer was deemed a special case for exceptional funding which fell outside
of the NICE remit, it has seen its budgets soar to over £280M, but it is still
not able to fund all of the treatments requested and recently a range of
drugs were removed from its approved list to prevent a predicted over-
spend of £100M. Commentators have suggested that the Fund is in difficulty
because it has not been able to use mechanisms to drive down the cost of treat-
ments, in the way that NICE has, and they have queried the extent to which
cancer drugs (as opposed to other kinds of treatments for cancer or other
serious diseases) should be a special case, given these high costs.50
However, a range of critics have condemned the Fund’s decision to ‘strike
50Anon, ‘The Cancer Drugs Fund Benign or malignant? A well-meaning gesture is causing more and more
trouble’ The Economist (London, 24 January 2015) http://www.economist.com/news/britain/21640343-
well-meaning-gesture-causing-more-and-more-trouble-benign-or-malignant (accessed 5 November
2015).
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off’ drugs from its approved list, on the basis that the benefits of the drugs to
individual patients are not being properly assessed.
The case of trastuzumab emtansine (Kadcyla) illustrates some of the
complex practices of patients and former patients which form part of these
processes of negotiation. Kadcyla, which costs an estimated £90,000 per
patient, reportedly prolongs life by six months longer than standard treatment
for women who carry the human epidermal growth factor 2 (HER2) gene
mutation, which affects an estimated one in five of women with advanced
breast cancer. In a recent ruling, NICE did not approve funding for
Kadcyla on the grounds that it was not cost effective. NICE determined
that the cost of the drug set by the manufacturer, Roche, far exceeded the
financial threshold of affordability of QALY of £20–30k. This has also been
true of seven other advanced breast cancer drugs that have been brought
forward for approval since 2011.51 The Cancer Drug Fund does fund
Kadcyla treatment but recently ruled that three other similar drugs would
only be available on a limited basis.
Breakthrough Breast Cancer has been among the organisations involved in
debating these decisions. In the case of NICE and Kadcyla they focused atten-
tion on the responsibility of Roche to price in a reasonable way, as did the
NICE Chief Executive Officer, Andrew Dillon.52 Patients’ experiences also
play a prominent role in these discussions, with patients talking about their
hopes, anger and disappointments with respect to their condition and its
treatment, as well as their wider sense of the obligations and entitlements
of citizenship and sickness. Patients, clinicians, support groups, charities
and manufacturers variously emphasised the benefits of accessing these
drugs in terms which challenged conventional measures of months-left-to-
live and focused on the vital time that this gives patients to spend with
their families, in relatively good health, for example, ‘giving women back a
normality to their lives’ in their final months.
These discussions were particularly emotive when conducted in the
national media, for example in the blog posts of journalists like Judith
Potts, of the Daily Telegraph.53 Potts’ tagline tells us she was diagnosed
with cancer in 2008, and this fact is used as a platform on which to build
her interventions in the cancer funding debates. She appeals to the
51Caroline White, ‘NICE Confirms Advanced Breast Cancer Drug is Too Expensive for NHS’ (2014) 349 British
Medical Journal g5078.
52Anon ‘NICE rejects ‘costly’ cancer treatment for NHS use’ National Health Executive, London, 23 April
2014 www.nationalhealthexecutive.com/Health-Care-News/Page-71/nice-rejects-costly-cancer-treatment-
for nhs-use (accessed 30 January 2015).
53See Judith Potts, ‘Is Nice shirking its duty of care by blocking the Abiraterone prostate cancer therapy?’
The Telegraph London February 3rd, 2012 http://blogs.telegraph.co.uk/news/judithpotts/100134923/is-
nice-shirking-its-duty-of-care-by-blocking-the-abiraterone-prostate-cancer-therapy/; Judith Potts, ‘Did
Nice listen to cancer patients when they rejected Abiraterone and Kadycla?’ The Telegraph London
August 15th, 2014 http://blogs.telegraph.co.uk/news/judithpotts/100283239/did-nice-listen-to-cancer-
patients-when-they-rejected-abiraterone-and-kadycla/ (accessed 17 October 2014).
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experiences of cancer patients when making her argument that these drugs
should be publically available. For example, Potts argues, ‘an extra six
months of life may seem very little to NICE but it allows the patient the
time to say goodbye, to put affairs in order, or perhaps attend a family
event’. Although acknowledging the high cost of the drugs, Potts points out
that the manufacturer has invested in development and needs to see a
return on this investment to be viable; she criticises NICE for being uncaring
and immoral for not giving the public a return on their National Insurance
payments by refusing to fund this drug. As Lakdawalla and colleagues have
argued, patients in these situations can prefer ‘hopeful gambles to safe bets’
and their involvement in lobbying regulatory processes is, in part, a matter
of trying to factor in the value of hope into Health Technology Assessment
algorithms.54
At the same time, patient groups are actively involved in taking these kinds
of arguments to the regulators, translating their and others’ experiences of
new expensive treatments into the kinds of evidence of ‘unmet need’ that
HTA bodies require. They are working together with governmental bodies,
NICE and pharmaceutical companies in a review of the Cancer Drug Fund
and its rising costs. Here patients’ representatives are doing political work,
drawing on their emotional connections and embodied experiences of
cancer to try to evaluate particular drugs, quantifying and justifying treatment
benefits as set against conventional treatments, e.g. extra time spent with
family and reduced side effects and, at the same time, acting as custodians
of the public interest, in the context of an ageing population. In other clinical
areas, hope is sustained through active efforts by patients to access experimen-
tal or unavailable treatments through ‘medical tourism’,55 rather than through
political lobbying.
These kinds of contributions also give insight into what is involved in being
on these kinds of treatments, when they are available. Decision-making about
the provision of drugs also takes place locally in the clinic and the regional
group in which it sits, and this can involve patients in active negotiation
with their clinician and administrative bodies to present their case for treat-
ment. Patients who are more affluent also have the option of purchasing
these drugs directly. Patients with a terminal diagnosis are involved in mana-
ging the uncertainties of their condition as well as their and their families’
hopes for a future that may not exist, as Brown and de Graaf have
argued.56 This can include ‘constructing, bracketing off or discounting the
54Darius N Lakdawalla, John A Romley, Yuri Sanchez et al, ‘How Cancer Patients Value Hope And The Impli-
cations For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies’ (2012) 31 Health Affairs 676.
55Alan Petersen, Kate Seear and Megan Munsie, ‘Therapeutic Journeys: The Hopeful Travails of Stem Cell
Tourists’ (2014) 36 Sociology of Health & Illness 670.
56Patrick Brown and Sabine de Graaf, ‘Considering a Future Which May Not Exist: The Construction of Time
and Expectations Amidst Advanced-Stage Cancer’ (2013) 15 Health, Risk & Society 543.
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value of the future’ as a way of coping with uncertainty. Patients also have to
weigh technical information as part of this process, for example risks, toxicity
and potential benefits, a process which cannot be performed without
emotional as well as cognitive work, including encounters with fear and
grief.57 They also have to build alliances and manage emotional connections
with care givers as part of their efforts to access particular treatments, again
practices that the most affluent and socially adept patients are much better
placed to perform than those with less social and cultural capital.
Our argument here is that these kinds of intervention are not simply a
matter of patient participation in or lobbying for regulation or treatment
decision, but in innovation more broadly. It is through the extended avail-
ability of novel drug therapies that companies are able to develop a viable
market and collect data on patient responses, enabling them to reconfigure
the treatment pathway, and other therapies under development. Patients’
variable responses to novel cancer treatment therapies are a crucial platform
for understanding the basic aetiology of cancer,58 so these kinds of patient
interventions in the politics of treatment are as much a constituent part of
the innovation process as the embodied practices and emotional work of
patients engaged in clinical trials and biobanking. Patient involvement in
public and policy discussion and debates about drug cancer treatment avail-
ability are also part of the innovation process given that it is as much a pol-
itical as a technical pursuit in the seamless web of contemporary
technoscience.
As with the case of trials and biobanks, however, we must also recognise
that the performance and reach of these kinds of patient practices is strati-
fied according to the cancer and the social location of the patients con-
cerned. Patients’ embodied interventions in innovation and regulation of
novel therapies is most obviously valued and appreciated in relation to
cancers which are already highly visible on the national public stage, and
tied into a wider set of political claims for legitimacy/support such as
breast cancer and women’s rights or prostate cancer and men’s rights:
cancers where patients ‘fight’ for treatment and rights simultaneously.59
These cancers are also preferred candidates for advocacy because there is
no strong moral discourse of individual responsibility for their develop-
ment, in contrast to the much more stigmatised lung cancer. This increases
the resonance of patients’ embodied advocacy for novel treatments, at the
same time implicitly de-legitimising claims for other kinds of treatments
or other kinds of diseases where individual rights are outweighed by
57Ajay Aggarwal and Richard Sullivan, ‘Affordability of Cancer Care in the United Kingdom: Is It Time to
Introduce User Charges?’ (2014) 2 Journal of Cancer Policy 31.
58Keating and Cambrosio (n 13).
59Gayle A Sulik, Pink Ribbon Blues: How Breast Cancer Culture Undermines Women’s Health (Oxford Univer-
sity Press, 2010).
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perceived responsibilities. Patients’ capacity to lay claim to entitlement to
novel therapies is also mediated by class and ethnicity, with cancers affect-
ing predominantly white and middle-class constituencies dominating claims
to expensive targeted treatments. Again, patients’ uneven entanglement in
the complexities of biomedical innovation and its effects demands a
range of emotional, cognitive, reflective, ethical and physical work.
5. Conclusion
In this short review of three key dimensions of contemporary cancer research
and treatments we have suggested that being a cancer patient nowadays
involves a variety of largely overlooked embodied or emotional work which
nevertheless makes a vital contribution to biomedical innovation in the
post-genomics era. We have also suggested that patients’ capacity or willing-
ness to engage in these practices is likely to be patterned according to their
social location and biological conditions and will vary according to the parti-
cularities of the research or regulatory process concerned. Patient partici-
pation and partnership with healthcare systems, biomedical research
platforms and the pharmaceutical industry is essential for the future success
of post-genomic medicine. Yet these developments rest on unexamined
requirements of the ‘work’ done by patients.
This suggests the need for further analysis of the different ways in which
some patients are contributing to innovation processes and with what
effects, and of how this compares with other practices which are considered
to be ‘work’, such as care. Analysis must also focus on how others are
perhaps more marginalised from these processes and opportunities, and
what the consequences of these exclusions might be for the kinds of inno-
vations being developed and patients’ experience of disease and healthcare.
It also suggests the need for further consideration of how we might account
for and give value to the largely hidden kinds of work that some patients
are doing as part of the innovation process.
This leads us to ask whether patients’ emotional management of hope,
obligation and entitlement (as well as the emotional ‘dirty work’60 of hand-
ling despair, alienation and anguish) should be transparently recognised as
part of the innovation process. This might mean a different form of
accounting for costs and benefits, including financially. Beginning to con-
ceptualise these activities as work has the potential to change how we
understand and manage participation in trials or biobanking initiatives,
helping us to understand why and how patients might take a stake in the
benefits generated by these initiatives. Possible avenues for taking this
60Robert McMurray and Jenna Ward, ‘“Why Would You Want to Do That?”: Defining Emotional Dirty Work’
(2014) 67 Human Relations 1123.
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forward could include participation in priority setting and consideration of
different models for benefit sharing or compensation for the work involved
in ‘being a patient’. Engaging with these issues about the value of patients’
work and the work of creating value in biomedical innovation is a crucial
task for policymakers, sociologists and ethicists in the post-genomics era.
Funding
This work was supported by the Wellcome Trust [104831/Z/14/Z].
Disclosure statement
No potential conflict of interest was reported by the authors.
Notes on contributors
Anne Kerr is Professor of Sociology and Head of School of Sociology and Social
Policy, University of Leeds. Sarah Cunningham-Burley is Professor of Medical and
Family Sociology; Head of School of Molecular, Genetic and Population Health
Sciences; Co-Director of Centre for Population Health Sciences; Co-Director,
Centre for Research on Families and Relationships; all at the University of Edinburgh.
LAW, INNOVATION AND TECHNOLOGY 205
